Skip to main content

Nutritional therapies in Parkinson’s disease

Current Treatment Options in Neurology volume 9, Article number: 198 (2007) Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and recommended Reading

  1. Savitt JM, Dawson VL, Dawson TM:Diagnosis and treatment of Parkinson disease: molecules to medicine.J Clin Invest 2006, 116:1744–1754.

    PubMed  Article  CAS  Google Scholar 

  2. Olanow CW, Jankovic J:Neuroprotective therapy in Parkinson’s disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.Mov Disord 2005, 20(Suppl 11):S3-S10.

    PubMed  Article  Google Scholar 

  3. VanItallie TB, Nonas C, Di Rocco A et al.:Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.Neurology 2005, 64:728–730.

    PubMed  CAS  Google Scholar 

  4. Apaydin H, Ertan S, Ozekmekci S:Broad bean (Vicia faba)—a natural source of L-dopa—prolongs “on” periods in patients with Parkinson’s disease who have “on-off” fluctuations.Mov Disord 2000, 15:164–166.

    PubMed  Article  CAS  Google Scholar 

  5. Rabey JM, Vered Y, Shabtai H et al.:Broad bean (Vicia faba) consumption and Parkinson’s disease.Adv Neurol 1993, 60:681–684.

    PubMed  CAS  Google Scholar 

  6. Rabey JM, Vered Y, Shabtai H, et al.:Improvement of parkinsonian features correlates with high plasma levodopa values after broad bean (Vicia faba) consumption.J Neurol Neurosurg Psychiatry 1992, 55:725–727.

    PubMed  Article  CAS  Google Scholar 

  7. Ladha SS, Walker R, Shill HA:Case of neuroleptic malignant-like syndrome precipitated by abrupt fava bean discontinuance.Mov Disord 2005, 20:630–631.

    PubMed  Article  Google Scholar 

  8. Manyam BV, Sanchez-Ramos JR:Traditional and complementary therapies in Parkinson’s disease.Adv Neurol 1999, 80:565–574.

    PubMed  CAS  Google Scholar 

  9. An alternative medicine treatment for Parkinson’s disease: results of a multicenter clinical trial. HP-200 in Parkinson’s Disease Study Group.J Altern Complement Med 1995, 1:249–255.

  10. Katzenschlager R, Evans A, Manson A, et al.:Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study.J Neurol Neurosurg Psychiatry 2004, 75:1672–1677.

    PubMed  Article  CAS  Google Scholar 

  11. Mena I, Cotzias GC:Protein intake and treatment of Parkinson’s disease with levodopa.N Engl J Med 1975, 292:181–184.

    PubMed  CAS  Google Scholar 

  12. Pincus JH, Barry KM:Plasma levels of amino acids correlate with motor fluctuations in parkinsonism.Arch Neurol 1987, 44:1006–1009.

    PubMed  CAS  Google Scholar 

  13. Pincus JH, Barry K:Influence of dietary protein on motor fluctuations in Parkinson’s disease.Arch Neurol 1987, 44:270–272.

    PubMed  CAS  Google Scholar 

  14. Pincus JH, Barry KM:Dietary method for reducing fluctuations in Parkinson’s disease.Yale J Biol Med 1987, 60:133–137.

    PubMed  CAS  Google Scholar 

  15. Pincus JH, Barry K:Protein redistribution diet restores motor function in patients with dopa-resistant “off” periods.Neurology 1988, 38:481–483.

    PubMed  CAS  Google Scholar 

  16. Karstaedt PJ, Pincus JH:Protein redistribution diet remains effective in patients with fluctuating parkinsonism.Arch Neurol 1992, 49:149–151.

    PubMed  CAS  Google Scholar 

  17. Pare S, Barr SI, Ross SE:Effect of daytime protein restriction on nutrient intakes of free-living Parkinson’s disease patients.Am J Clin Nutr 1992, 55:701–707.

    PubMed  CAS  Google Scholar 

  18. Berry EM, Growdon JH, Wurtman JJ, et al.:A balanced carbohydrate: protein diet in the management of Parkinson’s disease.Neurology 1991, 41:1295–1297.

    PubMed  CAS  Google Scholar 

  19. Baruzzi A, Contin M, Riva R, et al.:Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients.Clin Neuropharmacol 1987, 10:527–537.

    PubMed  Article  CAS  Google Scholar 

  20. Reilly DK, Hershey L, Rivera-Calimlim L, Shoulson I:On-off effects in Parkinson’s disease: a controlled investigation of ascorbic acid therapy.Adv Neurol 1983, 37:51–60.

    PubMed  CAS  Google Scholar 

  21. Tan EK, Cheah SY, Fook-Chong S, et al.:Functional COMT variant predicts response to high dose pyridoxine in Parkinson’s disease.Am J Med Genet B Neuropsychiatr Genet 2005, 137:1–4.

    Google Scholar 

  22. Djaldetti R, Baron J, Ziv I, Melamed E:Gastric emptying in Parkinson’s disease: patients with and without response fluctuations.Neurology 1996, 46:1051–1054.

    PubMed  CAS  Google Scholar 

  23. Pfeiffer RF:Gastrointestinal dysfunction in Parkinson’s disease.Lancet Neurol 2003, 2:107–116.

    PubMed  Article  Google Scholar 

  24. Gustafsson K, Ekblad J, Sidenvall B:Older women and dietary advice: occurrence, comprehension and compliance.J Hum Nutr Diet 2005, 18:453–460.

    PubMed  Article  CAS  Google Scholar 

  25. Ueki A, Otsuka M:Life style risks of Parkinson’s disease: association between decreased water intake and constipation.J Neurol 2004, 251 (Suppl 7):vII18-vII23.

    PubMed  Article  Google Scholar 

  26. Of major importance Drost J, Harris LA:Diagnosis and management of chronic constipation.JAAPA 2006, 19:24–29. A review outlining a comprehensive approach for chronic constipation management.

    PubMed  Google Scholar 

  27. Of importance Holick MF:The vitamin D epidemic and its health consequences.J Nutr 2005, 135:2739S-2748S. A good review on vitamin D.

    PubMed  CAS  Google Scholar 

  28. Lorefat B, Ganowiak W, Wissing U, et al.:Food habits and intake of nutrients in elderly patients with Parkinson’s disease.Gerontology 2006, 52:160–168.

    PubMed  Article  CAS  Google Scholar 

  29. Uc EY, Struck LK, Rodnitzky RL, et al.:Predictors of weight loss in Parkinson’s disease.Mov Disord 2006, 21:930–936.

    PubMed  Article  Google Scholar 

  30. Mamhidir AG, Ljunggren G, Kihlgren M, et al.:Underweight, weight loss and related risk factors among older adults in sheltered housing—a Swedish follow-up study.J Nutr Health Aging 2006, 10:255–262.

    PubMed  CAS  Google Scholar 

  31. Lorefalt B, Granerus AK, Unosson M:Avoidance of solid food in weight losing older patients with Parkinson’s disease.J Clin Nurs 2006, 15:1404–1412.

    PubMed  Article  Google Scholar 

  32. Of major importance Kashihara K:Weight loss in Parkinson’s disease.J Neurol 2006, 253(Suppl 7):vii38-vii41. Recent review of issues relating to weight loss in PD.

    PubMed  Article  Google Scholar 

  33. Bachmann CG, Trenkwalder C:Body weight in patients with Parkinson’s disease.Mov Disord 2006, 21:1824–1830.

    PubMed  Article  Google Scholar 

  34. Lorefalt B, Ganowiak W, Palhagen S, et al.:Factors of importance for weight loss in elderly patients with Parkinson’s disease Acta Neurol Scand 2004, 110:180–187.

    PubMed  Article  CAS  Google Scholar 

  35. Sienkiewicz-Jarosz H, Scinska A, Kuran W, et al.:Taste responses in patients with Parkinson’s disease.J Neurol Neurosurg Psychiatry 2005, 76:40–46.

    PubMed  Article  CAS  Google Scholar 

  36. D’Amelio M, Ragonese P, Morgante L, et al.:Long-term survival of Parkinson’s disease: a population-based study.J Neurol 2006, 253:33–37.

    PubMed  Article  Google Scholar 

  37. Hellenbrand W, Seidler A, Boeing H, et al.:Diet and Parkinson’s disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study.Neurology 1996, 47:636–643.

    PubMed  CAS  Google Scholar 

  38. Ondo WG, Ben-Aire L, Jankovic J, et al.:Weight gain following unilateral pallidotomy in Parkinson’s disease Acta Neurol Scand 2000, 101:79–84.

    PubMed  Article  CAS  Google Scholar 

  39. Nirenberg MJ, Waters C:Compulsive eating and weight gain related to dopamine agonist use.Mov Disord 2006, 21:524–529.

    PubMed  Article  Google Scholar 

  40. Wolfrath SC, Borenstein AR, Schwartz S, et al.:Use of nutritional supplements in parkinson’s disease patients.Mov Disord 2006, 21:1098–1101.

    PubMed  Article  Google Scholar 

  41. Rajendran PR, Thompson RE, Reich SG:The use of alternative therapies by patients with Parkinson’s disease.Neurology 2001, 57:790–794.

    PubMed  CAS  Google Scholar 

  42. Of major importance Suchowersky O, Gronseth G, Perlmutter J, et al.:Practice parameter: neuroprotective strategies and alternative therapies for Parkinson’s disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology 2006, 66:976–982. The American Academy of Neurology practice parameter on neuroprotective and alternative therapies for PD.

    PubMed  Article  CAS  Google Scholar 

  43. Of major importance Ishihara L, Brayne C:A systematic review of nutritional risk factors of Parkinson’s disease.Nutr Res Rev 2005, 18:259–282. A comprehensive meta-analysis and review of studies on nutritional risk factors for PD.

    PubMed  Article  CAS  Google Scholar 

  44. Etminan M, Gill SS, Samii A:Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis.Lancet Neurol 2005, 4:362–365.

    PubMed  Article  CAS  Google Scholar 

  45. Morens DM, Grandinetti A, Waslien CI, et al.:Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake.Neurology 1996, 46:1270–1274.

    PubMed  CAS  Google Scholar 

  46. DATATOP:a multicenter controlled clinical trial in early Parkinson’s disease. Parkinson Study Group.Arch Neurol 1989, 46:1052–1060.

    Google Scholar 

  47. Fahn S:An open trial of high-dosage antioxidants in early Parkinson’s disease.Am J Clin Nutr 1991, 53:380S-382S.

    PubMed  CAS  Google Scholar 

  48. Fahn S:A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease.Ann Neurol 1992, 32(Suppl):S128-S132.

    PubMed  Article  Google Scholar 

  49. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al.:Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.Ann Intern Med 2005, 142:37–46.

    PubMed  CAS  Google Scholar 

  50. Shults CW, Oakes D, Kieburtz K, et al.:Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.Arch Neurol 2002, 59:1541–1550.

    PubMed  Article  Google Scholar 

  51. Postuma RB, Espay AJ, Zadikoff C, et al.:Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.Neurology 2006, 66:1941–1943.

    PubMed  Article  CAS  Google Scholar 

  52. Hassin-Baer S, Cohen O, Vakil E, et al.:Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.Clin Neuropharmacol 2006, 29:305–311.

    PubMed  Article  CAS  Google Scholar 

  53. Todorovic Z, Dzoljic E, Novakovic I, et al.:Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson’s disease, with and without levodopa therapy.J Neurol Sci 2006, 248:56–61.

    PubMed  Article  CAS  Google Scholar 

  54. Sato Y, Iwamoto J, Kanoko T, Satoh K:Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson’s disease.Am J Med 2005, 118:1250–1255.

    PubMed  Article  CAS  Google Scholar 

  55. Nakayama Y, Washio M, Mori M:Oral health conditions in patients with Parkinson’s disease.J Epidemiol 2004, 14:143–150.

    PubMed  Article  Google Scholar 

  56. Schwarz J, Heimhilger E, Storch A:Increased periodontal pathology in Parkinson’s disease.J Neurol 2006, 253:608–611.

    PubMed  Article  Google Scholar 

  57. Hathcock JN, Shao A:Risk assessment for coenzyme Q10 (ubiquinone).Regul Toxicol Pharmacol 2006, 45:282–288.

    PubMed  Article  CAS  Google Scholar 

  58. Lheureux P, Penaloza A, Gris M:Pyridoxine in clinical toxicology: a review.Eur J Emerg Med 2005, 12:78–85.

    PubMed  Article  Google Scholar 

  59. Callahan CM, Buchanan NN,, Stump TE:Healthcare costs associated with percutaneous endoscopic gastrotomy among older adults in a defined community.J Am Geriatr Soc 2001, 49:1525–1529.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurology, Movement Disorders Section, Emory, University School of Medicine, 1841 Clifton Road NE, 30329, Atlanta, GA, USA

    Marian L. Evatt MD

Authors
  1. Marian L. Evatt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marian L. Evatt MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Evatt, M.L. Nutritional therapies in Parkinson’s disease. Curr Treat Options Neurol 9, 198 (2007). https://doi.org/10.1007/BF02938409

Download citation

  • DOI: https://doi.org/10.1007/BF02938409

Keywords

  • Levodopa
  • Percutaneous Endoscopic Gastrostomy
  • Motor Fluctuation
  • Tegaserod
  • Recommend Dietary Allowance